Viatris (VTRS) CFO Paul Campbell Sells $810K of Stock
Paul Campbell sold 50,076 shares of Viatris Inc., valued at $809,728.92, on June 25, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Paul Campbell, Interim Chief Financial Officer, Chief Accounting Officer and Corporate Controller at Viatris Inc. ($VTRS), sold 50,076 shares at an average price of $16.17, worth about $809,728.92, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $VTRS is up 4.0% after 1 week, up 9.8% after 1 month and up 17.0% to date (from the $15.95 close on Jun 25, 2026).
VTRS
Viatris Inc.
Key Points
- Paul Campbell, Interim CFO of Viatris Inc., sold 50,076 shares at $16.17 each, totaling $809,728.92 on June 25, 2026.
- On Sunday, Viatris Inc. shares traded near $16.33 with a market cap of about $19 billion and a forward P/E of 6.13.
- Analysts like Barclays and JP Morgan have maintained their ratings, with price targets ranging from $12 to $22.
Get $VTRS trade alerts by text
We text you when insiders, Congress or big funds trade $VTRS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Viatris Inc. alert may contain errors. Disclosures
Paul Campbell, the Interim Chief Financial Officer at Viatris Inc., sold 50,076 shares of the company on June 25, 2026. The shares were sold at an average price of $16.17, making the transaction worth about $809,728.92. This sale was part of a planned transaction under Rule 10b5-1.
Insider Buying and Selling at Viatris Inc.
Paul Campbell, who also serves as the Chief Accounting Officer and Corporate Controller, executed this planned sale. Another notable insider activity involved Corinne Le Goff, the Chief Commercial Officer, who had both purchases and sales on April 15, 2026. Le Goff sold 19,067 shares at $13.86, among other transactions.
Viatris Inc. Stock Down 3.7%
Shares of NasdaqGS:VTRS traded near $16.33 on Sunday. Viatris Inc. has a market capitalization of approximately $19 billion. It features a forward P/E ratio of 6.13 and a beta of 0.901, indicating moderate volatility. Over the past year, the stock has ranged from $8.63 to $17.53. Its 50-day moving average is $15.86, while the 200-day moving average stands at $13.10.
Analysts Set New Price Targets
On May 19, 2026, Barclays maintained a 'buy' rating on Viatris with a price target of $22. JP Morgan and Truist Securities also maintained their ratings on May 8, 2026, with targets of $18 and $20, respectively. The consensus target price among analysts is about $17.81, based on eight opinions.
About Viatris Inc.
Viatris Inc. is a global healthcare company headquartered in Canonsburg, Pennsylvania. It operates in various regions including North America, Europe, and Asia. The company offers a wide range of prescription and generic drugs, biosimilars, and over-the-counter products. Led by CEO Scott Andrew Smith, Viatris employs around 30,000 people and focuses on providing access to high-quality medicines.
Bottom Line
Insider transactions like Paul Campbell's planned sale are closely watched by investors for potential insights into company sentiment. Viatris Inc. continues to be a significant player in the healthcare sector with a broad portfolio of products. Investors should note that 13F filings and insider sales are typically backward-looking, reflecting past actions rather than current intentions.
Related Filing Alerts
Source: Paul Campbell's Form 4 filing on $VTRS (Jun 25, 2026). Find the original filing: VTRS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts